The Lung Inflammatory Disease Program of Excellence in Glycosciences (LID-PEG) has Projects and Cores at three institutions and a breadth of capabilities ranging from chemistry to preclinical therapeutic models. With this diversity, communications will be a key to LID-PEG progress and success. A major role in effective communication will be provided by Core A, the Administrative Core. Core A will take responsibility for inter-program communications both through web-based video conferencing and face-to-face meetings. The Core will coordinate and oversee the regular video-conference meetings of the Executive Committee, organize the annual Program Group Meeting (which will rotate among the three sites), organize meetings of the LID-PEG with its Internal and External advisory boards and support LID-PEG participation in the annual Investigator's meeting in Bethesda. In addition to travel planning and reimbursement for LID-PEG meeting participants. Core A will coordinate communications with NHLBI and the Administrative Center, manage budgets and fulfill NIH reporting requirements.

Public Health Relevance

This Program brings together scientists from across the country to combine diverse expertise in glycosciences with the goal of discovering new therapies for asthma, COPD and other lung and cardiovascular inflammatory diseases. Effective communication is essential to this goal, and Core A will take the lead in ensuring efficient communications among LID-PEG members.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL107151-03
Application #
8477259
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$145,858
Indirect Cost
$57,398
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
O'Sullivan, Jeremy A; Bochner, Bruce S (2017) Eosinophils and eosinophil-associated diseases: An update. J Allergy Clin Immunol :
Yu, Huifeng; Gonzalez-Gil, Anabel; Wei, Yadong et al. (2017) Siglec-8 and Siglec-9 binding specificities and endogenous airway ligand distributions and properties. Glycobiology 27:657-668
O'Sullivan, Jeremy A; Carroll, Daniela J; Cao, Yun et al. (2017) Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells. J Allergy Clin Immunol :
Carroll, Daniela J; O'Sullivan, Jeremy A; Nix, David B et al. (2017) Sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8) is an activating receptor mediating ?2-integrin-dependent function in human eosinophils. J Allergy Clin Immunol :
Guo, Hongbo; de Vries, Erik; McBride, Ryan et al. (2017) Highly Pathogenic Influenza A(H5Nx) Viruses with Altered H5 Receptor-Binding Specificity. Emerg Infect Dis 23:220-231
Lou, Hongfei; Lu, Jingning; Choi, Eun Byul et al. (2017) Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway. J Immunol 198:2543-2555
Peng, Wenjie; Paulson, James C (2017) CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells. J Am Chem Soc 139:12450-12458
Schnaar, Ronald L; Lee, Yuan C (2017) Discoveries of the structures of sialic acid and CMP-sialic acid (1957-1960): A letter from Saul Roseman. Glycobiology :
Wu, Nicholas C; Xie, Jia; Zheng, Tianqing et al. (2017) Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin. Cell Host Microbe 21:742-753.e8
Schleimer, Robert P; Schnaar, Ronald L; Bochner, Bruce S (2016) Regulation of airway inflammation by Siglec-8 and Siglec-9 sialoglycan ligand expression. Curr Opin Allergy Clin Immunol 16:24-30

Showing the most recent 10 out of 65 publications